3 October 2016
IXICO plc
("IXICO" or the "Company")
Appointment of Shore Capital as Nominated Adviser & Sole Broker
IXICO plc (AIM: IXI), the brain health company, announces the appointment of Shore Capital and Corporate Limited as Nominated Adviser and Shore Capital Stockbrokers Limited as sole Broker, (together "Shore Capital"), with immediate effect.
For further information please contact:
IXICO plc Derek Hill, Chief Executive Officer Susan Lowther, Chief Financial Officer |
Tel: +44 20 3763 7499 |
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield |
Tel: +44 20 7408 4090 |
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan/Matthew Moss |
Tel: +44 20 3727 1000 |
About IXICO
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
